Nobokin 200 mg (Tablet)
Unit Price: ৳ 300.00 (4 x 8: ৳ 9,600.00)
Strip Price: ৳ 2,400.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sorafenib tosylate |
| Company | Genvio pharma ltd |
Indications
- Unresectable hepatocellular carcinoma (HCC)
- Advanced renal cell carcinoma (RCC)
Pharmacology
Kinase inhibitor, decreases tumor cell proliferation, inhibits multiple intracellular and cell surface kinases, involved in tumor cell signaling, angiogenesis, and apoptosis, inhibits tumor growth and angiogenesis
Dosage & Administration
- Recommended daily dose of 400 mg tablets taken twice daily without food
- Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs
- Management of suspected adverse drug reactions may require temporary interruption and/or dose reduction of therapy
Interaction
- Contraindicated in patients with squamous cell lung cancer when in combination with carboplatin and paclitaxel
- May increase systemic exposure to substrates of UGT1A1 and UGT1A9
- Caution recommended when co-administered with Docetaxel, Doxorubicin, Fluorouracil, CYP2B6 and CYP2C8 substrates, CYP3A4 inducers, CYP3A4 inhibitors, and P-glycoprotein substrates
- Had no effect on the pharmacokinetics of gemcitabine or oxaliplatin
- Coadministration with oral Neomycin should be carefully considered
Contraindications
- Known severe hypersensitivity to Sorafenib or any other component
- In combination with carboplatin and paclitaxel in patients with squamous cell lung cancer
Side Effects
- Cardiac ischemia
- Infarction
- Hemorrhage
- Hypertension
- Hand-foot skin reaction
- Rash
- Gastrointestinal perforation
- Wound healing complications
Pregnancy & Lactation
May cause fetal harm when administered to a pregnant woman, excretion in human milk unknown
Precautions & Warnings
- Temporary or permanent discontinuation of therapy should be considered in patients who develop cardiac ischemia and/or infarction
- Increased risk of bleeding following administration
- Increased risk of hypertension
- Hand-foot skin reaction and rash are common adverse reactions
- In the event of gastrointestinal perforation, therapy should be discontinued
- Monitoring recommended for patients taking concomitant warfarin
- Resume therapy following major surgical intervention should be based on clinical judgment of adequate wound healing
- Higher mortality observed in patients with squamous cell carcinoma when in combination with carboplatin and paclitaxel
- Can cause increases in plasma concentrations of UGT1A1 substrates, Docetaxel, and Doxorubicin
- Hepatic impairment may reduce plasma concentrations
- Co-administration of oral Neomycin causes a decrease in exposure
Use in Special Populations
- Safety and effectiveness in pediatric patients not studied
- No differences in safety or efficacy observed between older and younger patients
- No dose adjustment required for patients with any degree of renal impairment
- Lower AUCs observed in patients with mild and moderate hepatic impairment
Overdose Effects
No specific treatment for overdose, highest clinically studied dose is 800 mg twice daily, adverse reactions primarily diarrhea and dermatologic
Therapeutic Class
Targeted Cancer Therapy
Storage Conditions
Store at room temperature below 30°C, do not remove desiccant, dispense in original bottle